Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck issued guidance for 2025 that lags consensus ... after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine in China overshadowed a quarterly earnings beat.

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

As more cancers are being linked to the human papillomavirus (HPV), including cancers showing up in younger-than-average patients, a local doctor is promoting the use of the HPV vaccine, which is ...

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

Merck swung to a quarterly profit as sales grew to beat Wall Street's estimates, though the drug company's outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.

Background: While prophylactic human papilloma virus (HPV) vaccination is considered ... Meta-analyses were performed, assuming both random and fixed effects, to estimate risk ratios (RR) and ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...